Here are the top 10 journal articles and some of the most discussed on Twitter for the week of June 7, 2021.
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Journal Of Clinical Oncology
Paul Richardson, Philippe Moreau
What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma.
Journal Of Clinical Oncology
Anita D’Souza, Sagar Lonial
Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma.
Blood
Larissa Haertle, K Martin Kortüm
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods.
Leukemia
Jill Corre, Intergroupe Francophone Du Myélome (IFM)
Correction to: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signaling.
Leukemia
Antoine David, David Garrick
A CNN-based unified framework utilizing projection loss in unison with label noise handling for multiple Myeloma cancer diagnosis.<
Medical Image Analysis
Shiv Gehlot, Ritu Gupta
The immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.
The FEBS Journal
Tommaso Perini, Enrico Milan
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.
Molecular Cancer
Chunyan Gu, Ye Yang
Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma.
Lancet
Michele Cavo, Elena Zamagni
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Lancet
Philippe Moreau, IKEMA Study Group